arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Ocugen, Inc.

OCGN
$1.27 ▲ +0.02 (+2.00%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
13 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
86
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Ocugen, Inc. shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap
Dividend Yield
Revenue Growth 8.8%
Op. Margin
ROIC -409.2%
FCF / Share None
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -2.26
info Valuation on last close. End-of-day price, Aug 7, 2026.

13-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.41M
↑ +8.8%
Net Income Profit after all expenses
$-67.85M
↓ -25.5%
FCF / Share Free cash flow per share
$-0.30
↑ +1.3%
Long-Term Debt Long-term obligations
$27.54M
↑ +0.7%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Financial Health
100
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 50 quarters